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More than 350 million people worldwide are persistently infected with human heptatitis B virus (HBV) and at risk to develop
liver cirrhosis and hepatocellular carcinoma making long-term treatment necessary. While a vaccine is available and new antiviral
drugs are being developed, elimination of persistently infected cells is still a major issue. Recent eﬀorts in adoptive cell therapy are
experimentally exploring immunotherapeutic elimination of HBV-infected cells by means of a biological attack with genetically
engineered “designer” T cells.
1.PersistentHepatitisBVirusInfectionin
the LiverIs atRisktoDevelop Cirrhosisand
HepatocellularCarcinoma
Human hepatitis B virus (HBV) is an enveloped, DNA
virus with an icosaedral capsid, which belongs to the family
of hepadnaviridae with a very narrow host range and
a strong liver tropism. HBV has a 3.2kb DNA genome
in an extremely compact organisation containing four
unidirectional overlapping open reading frames. Following
infection the relaxed circular (rc) viral DNA is transported
into the nucleus where it is ﬁlled up to form the so-
called covalently closed circular DNA (cccDNA) in the
nucleus which serves as template for transcription of the
pregenomic, the precore and three subgenomic RNAs. The
pre-genomic RNA is translated into the polymerase and the
viral core protein and is encapsidated together with the HBV
polymerase into the newly formd viral capsid. The pre-core
RNA encodes the secretory HBeAg. Subgenomic RNAs are
translated into the large (L), middle (M), and small (S)
viralenvelopeproteinsandtheregulatoryproteinX.Infected
c e l l ss e c r e t ec o m p l e t ev i r i o n sa sw e l la ss u b v i r a lp a r t i c l e s
which represent empty envelopes packed with S protein.
Detection of subviral particles in the serum as HBsAg can
be used to identify HBV infected individuals (for review, see
[1, 2]).
While infection during the ﬁrst year of life results in
chronic, often life-long infection in >90% of individuals,
infectionduring adulthood ismostlyclearedresultingin life-
long protective immunity. Clearance is accompanied by a
vigorous, polyclonal HBV-speciﬁc T cell response. Persistent
liver infection may cause substantial inﬂammatory liver
disease associated with elevation of serum transaminases,
necroinﬂammation, and tissue damage, which is classiﬁed
as chronic hepatitis B. More than 25% of chronic hepatitis
B patients develop progressive liver disease resulting in
liver cirrhosis and/or hepatocellular carcinoma; 15%−40%
of patients develop serious sequelae accounting for 0.6
to 1.2 million deaths worldwide per year. These ﬁgures
demonstrate the urgent need in improving therapeutic
strategies for the treatment of chronic hepatitis B.
2. Current Therapeutic Options in HBV
EliminationAre Limited:A Rationale for
a Cellular ImmuneTherapeutic Approach
Current therapeutic options in the treatment of chronic
hepatitis B aim to suppress HBV replication and to induce2 Hepatitis Research and Treatment
remission of liver disease [3, 4] based on the fact that high
viraemia is the major risk for progression of HBV-related
liver disease and development of haptocellular carcinoma
[5]. Standard treatment includes IFN-α or nucleoside or
nucleotide analogues. IFN-α has direct anti-viral activity and
moreover immune modulatory capacities, thereby stimulat-
ing the host immune response. Seroconversion of HBeAg
positive patients to anti-HBe and loss of serum HBV DNA,
however, occurs only in about 20% of treated patients and
full immunological control of the virus indicated by loss of
the HBsAg in maximally 5% [6]. In many cases, moreover,
response to treatment is not durable.
IFN-α therapy is a diﬃcult treatment option for a
number of applications and excludes therapy of advanced
or decompensated liver disease due to severe side eﬀects
including hepatitis ﬂares,fever,myalgias,thrombocytopenia,
and psychic depression. Many inhibition of viral reverse
transcriptase by nucleoside analogues impairs the viral life
cycle but does not target the episomal replication template in
the host cell allowing HBV cccDNA to persist. HBV cccDNA
can persist even at low copy numbers in infected cells for
months and years, being the initiating template for a new
HBV replication cycle after the end of therapy which often
results in disease relapse [7]. DNA containing capsids can
replenish cccDNA in infected cells which makes a complete
block in replication for a prolonged time span mandatory in
ordertoeliminatecccDNAduringcelldivision.Althoughthe
half-lifetimeinhumansisunknown,datafromexperimental
systems imply a half-life of 9−14 days in chimpanzees and up
to 50 days in duck and wookchuck models under therapy
[8, 9]. Nucleoside analogues control HBV replication but
usually do not eliminate the virus. Long-term, highly potent
antiviral therapy using nucleotide analogue adefovir reduced
virus replication and cccDNA levels; HBV cccDNA persists
in the host cell, continuously produces HBsAg, and remains
the potential source of viral rebound and disease recurrence
after initial successful therapy. The overall number of HBV
antigen positive cells, however, remains constant [10]. In
patients who do not serocovert from HBsAg to anti-HBs,
virus still persists in 5%−30% of hepatocytes indicated by
HBsAg expression [11]. This situation makes long-term
treatment necessary which, however, increases the risk for
selecting resistant virus variants leading to hepatitis ﬂares
and hepatic decompensation [12]. Newly developed more
potent nucleos(t)ide analogues avoid rapid development of
therapy resistance. However, sustained immunological con-
trol of HBV infection, as substantiated by the loss of HBsAg
and sustained loss of virus replication is so far very rarely
achieved [13]. As a consequence, long-term or even life-
long treatment is required and/or a persistent host anti-HBV
immuneresponsehastobeestablished.Thismaybeachieved
by therapeutic vaccination to induce a speciﬁc antibody
response or by adoptive transfer of HBV, speciﬁc T cells.
Vaccination is currently the most eﬀective measure to
reduce the global incidence of hepatitis B (for review, see
[14]). Hepatitis B vaccination has been shown to preclude
HBV infection eﬀectively when used as a preexposure pro-
phylaxis.RecombinanthepatitisBvaccinesarewelltolerated.
Side eﬀects are generally mild, transient, and conﬁned to
the site of injection. Although safety of the vaccine has
been questioned in recent years severe side eﬀects could
not be demonstrated. In particular, some cases of relapse
of multiple sclerosis or other demyelinating diseases were
reported; the WHO Global Advisory Committee on Vaccine
Safetyconcludedthatthereportedevidencedoesnotsupport
a link to hepatitis B vaccination.
Following a full course of vaccination seroprotection in
a preventive setting based on anti-HBsAg antibodies is close
to 100% in children and almost 95% in healthy young adults
and persists for at least 10 to 15 years once a good response
has been achieved. In successfully immunized people clini-
callysigniﬁcantbreakthroughinfections arerare.Toenhance
immunogenicity and to confer more rapid and broader
protection from hepatitis B, a new vaccine incorporating a
noveladjuvanthasrecentlybeenapproved.Third-generation
recombinant triple-antigen vaccines including pre-S1, pre-
S2 and S antigen showed more eﬀective for revaccination of
people who are immune suppressed or had an inadequate
response to current vaccines. Antibodies to the hepatitis B
surface antigen are mainly targeted to bind the amino acid
hydrophilic region, referred to as the “a” determinant of
HBsAg, which provides protection against infection with all
HBV genotypes and is responsible for the broad immunity
aﬀordedbyhepatitisBvaccination.Viralvariantswithamino
acid mutations in this region can escape antibody binding
[15, 16] and hence infections in previously successfully
vaccinated individuals.
Taken together, vaccination remains the most eﬀective
means of preventing hepatitis B, liver cirrhosis and hepato-
cellular carcinoma. Compared to therapeutic interventions,
vaccination is an economically attractive option, both in
terms of cost-eﬀectiveness and beneﬁt-cost ratios. Once
infection has established, however, vaccination with cur-
rently available vaccines is not eﬀective.
The major limitation of vaccination is that it so far
has no proven eﬀect in HBV infected individuals. Adoptive
transfer of cytotoxic T lymphocytes (CTLs) with speciﬁcity
for HBsAg positive cells may represent an approach aiming
to ultimately eliminate residual hepatocytes carrying HBV
cccDNA. The rationale for adoptive T cell transfer in
hepatitis B therapy is moreover given by the observation that
a polyclonal CTL response with multiple speciﬁcities occurs
in patients who had cleared acute infection [17, 18]w h e r e a s
an oligoclonal and weak response is found in chronically
infected individuals [19, 20]. While obviously capable in
inducing viral clearance, CTLs are also thought to be also
responsible for liver injury during HBV infection [21]. The
latter may eventually cause hepatocellular carcinoma if the
virus is not cleared and chronic inﬂammation persists. Two
third HBV-infected leukaemia patients who occasionally
received human progenitor cell transplants from HBV
immune donors cleared their HBV infection [22]. Taken
together, current data encourage the development of an
adoptive T cell therapy to control not only virus replication
but also disease progression.
Adoptive T cell therapy recently showed substantial suc-
cess in cancer immunotherapy after lymphodepletion [23–
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leukaemia after allogeneic bone marrow transplantation
and in Epstein-Barr virus-associated posttransplant lym-
phoproliferative disorders [27, 28]. Therapeutic eﬃcacy in
malignant diseases provides a strong rationale to develop
adoptive T cell therapy also for chronic infectious diseases
[18, 29]. Progress in the engineering of an artiﬁcial T cell
receptor to deliver antibody like speciﬁcity in the context of a
T cell activation signal [30] enables redirecting a cytolytic T
cell response to predeﬁned target cells as discussed below.
3. Adoptive Cell Therapy with
GeneticallyModiﬁedTCellsSpeciﬁcally
Redirects the Immune Response
EarlyattemptstoengineerTcellswithpre-deﬁnedspeciﬁcity
included the transgenic expression of a T cell receptor (TCR)
resulting in genetically modiﬁed T cells which display the
newspeciﬁcitytogetherwiththeendogenousTCRandwhich
can be ampliﬁed to substantial numbers ex vivo before
transplantation to the patient. Diﬃculties rose, however,
in engrafting both recombinant TCR chains with suﬃcient
eﬃcacy. Lethal cytokine-driven autoimmune pathology can
occur due to pairing of the introduced recombinant with
the endogenous TCR chains in TCR gene-modiﬁed T cells
[31]. This potential risk will not occur in the using of
single chain chimeric receptors as outlined below. Most
target cells, moreover, show defects in antigen processing
and MHC presentation making them invisible for TCR
recognition. This situation has led to the development of
a chimeric, MHC-independent one-polypeptide receptor
molecule whose antigen-binding domain is derived from
an antibody and the signalling domain from the TCR. The
archetypal chimeric antigen receptor (CAR; immunorecep-
tor), nicknamed “T-body”, consists of an extracellular single
chain fragment of variable region antibody which is fused
to the transmembrane and cytoplasmic domain providing
signalling moieties, frequently the CD3ζ of the TCR. Due to
its one-polypeptide chain design and modular composition,
CARs substantially improved the technology in redirecting T
cellsbycombiningdiﬀerentadvantages(Table 1).Uponanti-
gen engagement of the extracellular domain, the signalling
endodomain initiates T cell activation resulting in T cell
ampliﬁcation, secretion of proinﬂammatory cytokines, and
cytolysis of those cells which express the targeted antigen
on the cell surface. There are major diﬀerences between
the TCR and a CAR since CARs are not MHC-restricted
thus recognizing antigens not necessarily presented by the
MHC. CAR redirected T cells can thereby target cells with
established immune escape mechanisms like down MHC
regulation or reduced endolysosomal antigen processing. An
additional advantage with particular relevance for clinical
applicationsisthataCARrecognisestargetswhichareshared
by many individuals independently of their MHC haplotype.
Optimisation the individual CAR domains has been a
long standing focus of research, in most cases with respect
to deliver the appropriate T cell activation and to provide
sustained survival signals (for details, we refer to recent
reviews [30, 32]). The modular structure enabled further
Table 1: Advantages and disadvantages of CAR redirected T cell
therapy.
Advantages Disadvantages
MHC-independent antigen
targeting
empirical testing of newly
generated CARs required
High aﬃnity binding
optimal T cell-to-target cell
spacing distance required for T
cell activation
Allows production of high
numbers of antigen-speciﬁc,
patient-derived T cells
individual engineering of
p a t i e n t ’ sTc e l l sn e c e s s a r y
allows redirecting CD4+ and
CD8+ Tc e l l s
short-term persistence of
engineered T cells in vivo
redirection towards a broad
variety of targets possible
T cell expansion may reduce
reactivity
T cell expansion upon antigen
engagement
antigen cross-reactivity
increases risk of “oﬀ-target”
activation and autoimmunity
Repetitive killing possible soluble antigen may block T cell
activation
additions of signalling domains to the cytoplasmatic part,
for example, costimulatory domains to endow T cells with
full activation potential independent of the costimulatory
ligand on target cells [33, 34]. CAR engineering together
with eﬃcient and safe technologies for gene transfer to T
cells using γ-retroviral or lentiviral vectors have become
the method of choice to redirect speciﬁcity of T cells for
adoptive cell therapy. The technical procedures to engineer
redirected T cells from patient peripheral blood T cells have
been adapted to a GMP conform process [35, 36]. The
majority of CARs were generated to target antigens (non-
exclusively) expressed on cancer cells; the focus of research
on CAR redirected immunotherapy is therefore dedicated
to cancer therapy (we refer to recent reviews [28, 30, 32]).
While CAR modiﬁed T cells for the elimination of cancer
cells is currently evaluated in clinical trials, interest is raising
toredirectcytotoxicTcellstopersistentlyvirusinfectedcells,
cells of major interest are human immunodeﬁciency virus-1-
(HIV-1-) infected T cells [37] and HBV-infected hepatocytes
[34] displaying viral proteins on the cell surface.
4.EngineeredTCellswith
SpeciﬁcityforHBVInfectedCellsProvide
aN o v elT h e rape u ticOptio n
HBV-infected cells continuously produce HBsAg which is
mainly composed out of the HBV S with trace amounts of
M and large L surface proteins [38]. The HBV antigens are
present on the surface of HBV replicating cells [39], based on
the fact that HBV surface proteins are incorporated into the
ER membrane which is in steady exchange with the plasma
membrane. The proteins are, moreover, a sensitive and
speciﬁc marker for active viral replication in HBV infected
cells.Theseproteinstherebyrepresentpotentialtargetsforan
adoptivecelltherapyusingredirectedcytotoxiclymphocytes.
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surface antigens, L- and S-protein, were described to redirect
a cytolytic T cell response to HBV infected hepatocytes
[40]. Upon S-protein engagement and to a lesser extent by
targeting L-antigen, CAR engineered T cells were activated
to secrete proinﬂammatory cytokines, to proliferate and to
eliminate HBV-replicating hepatoma cells as well as HBV
infected primary human hepatocytes in vitro.
Since the choice of the CAR-binding domain is of
particular relevance for the clinical success of an adoptive
T cell therapy, an scFv antibody was used for targeting
which is directed against a conformational epitope in the
“a” determinant of S-protein [41]. This antibody showed
highest binding eﬃciency and speciﬁcity and proved most
eﬀective and speciﬁc in CAR redirected T cell activation. To
obtain a suitable scFv against L-protein, which is only in
trace amounts present in subviral particles, a scFv antibody
was derived from the well-established monoclonal antibody
5a19.AntigenrecognitionbyCARengineeredTcellsresulted
in high-level IFN-γ secretion in vitro. Secreted IFN-γ is
assumed to control HBV replication thereby itself exhibiting
anantiviraleﬀect[42,43].BycombiningtheCD3ζ signalling
domain with the CD28 costimulatory moiety in a so-
called“secondgeneration”CARIL-2secretionisadditionally
induced providing full T cell activation. Although the
targeted antigens are expressed on diﬀerent levels both anti-
S and anti-L CAR engineered T cells lysed with similar eﬃ-
ciencies HBV-replicating hepatoma cells and HBV infected
primary human hepatocytes. However, cytokine levels, and
particularly IL-2 levels, were markedly higher when T cells
grafted with anti-S CAR were used in comparison to anti-
L CAR-engineered T cells. This diﬀerence is likely to be
due to the high abundance of the S-protein expressed and
subsequently displayed on the surface of HBV infected
cells and is reﬂected by time course experiments which
showed accelerated activation kinetics of S-speciﬁc CAR in
comparison to L-speciﬁc T cells.
CAR engineered T-cells bind not only HBV-infected cells
but also soluble HBV particles leading to NF-κBa c t i v a t i o n
and IFN-γ secretion indicating that the surface area of
HBV viral and subviral particles is suﬃcient to induce
CAR clustering. This is in contrast to soluble monomeric
proteins like CEA which does not induce CAR-mediated T
cell activation due to lack of CAR clustering [44]. Anti-HIV-
1 gp120 CAR engineered T cells, for comparison, are less
eﬃciently activated by the monomeric soluble gp120 than
by binding to the transmembrane protein of infected cells
[37]. This does, however, neither lead to killing of infected
hepatocytes incubated with viral and subrial particles nor
impair cytolytic activity of anti-HBV CAR T cells in vitro by
soluble HBV particles in HBsAg levels of up to 250ng/mL,
relating to approximately 40,000 particles per T cell [32].
Using primary human hepatocytes infected with HBV as
targets and primary T cells from the same donor for engi-
neering with anti-S and anti-L CAR, engrafted T cells were
activated for hepatocyte killing. About 10−20% hepatocytes
were in vitro infected, engineered T cells speciﬁcally killed a
subfraction of hepatocytes. HBV-infected hepatocytes were
eliminated since >95% HBV cccDNA was eliminated from
HBV infected hepatocyte cultures by anti-S CAR and >80%
by anti-L CAR engineered T cells [40]. This strongly argues
for speciﬁc elimination of HBV-infected hepatocytes [9, 45].
The conclusion is, moreover, sustained by the observation
that levels of total intracellular HBV core protein were
reduced by 73% by anti-S and by 57% by anti-L CAR
T cells, levels of intracellular HBV rcDNA by 82% and
72%, respectively, whereas intracellular albumin indicating
viabilityofhepatocytecellpopulationwasonlyreducedby17
and14%,respectively.Thedatadonotexclude,however,that
activationofCARredirectedTcellscouldbeaccompaniedto
some extend by unspeciﬁc killing of uninfected hepatocytes
in the neighbourhood of infected cells, so-called bystander
killing.
CAR redirected T cells lyse their targets predominantly
via granzyme/perforin. Accordingly, Lamp-2 staining on
the surface of anti-S CAR T cells indicated degranulation
of lytic granules upon contact to target cells. Additionally
activation of eﬀector caspase-3 and -7 were detected in
targeted hepatocytes and cytotoxicity was blocked by a
pan-caspase inhibitor. We, therefore, expected induction of
caspase activated DNases which will degrade histone-bound
nuclear cccDNA. HBV rcDNA which is encapsidated in viral
capsids, however, was protected by the core protein and
not degraded in consequence of a cytolytic T cell attack of
infected cells.
Beside CTL mediated cytolysis of infected target cells,
noncytolytic processes may equally contribute to the reduc-
tion of HBV cccDNA. The assumption is based on the obser-
vations that no massive hepatocyte lysis occurs during recov-
eryofchimpanzeesfromHBVinfection[46]andthenumber
of CD8+ T cells inﬁltrating the liver does not correlate with
the level of hepatocyte lysis [47]. CAR engineered T cells
secrete proinﬂammatory, anti-viral cytokines, in particular
type-1 interferon and TNF-α, which potentially can suppress
viral replication through non-cytolytic, immune-mediated
mechanisms which also contribute to diminish the cccDNA
reservoirs from infected cells [46] because they kill infected
cells and induce divison of hepatocytes which then are prone
to loose cccDNA [48]. In the absence of cell division and
in the chronic phase of the disease, these processes may be
ineﬀective and cccDNA will persist with the long half-life of
hepatocytes.
HBV-infection may also be controlled by an innate
response mediated by Kupﬀer cells and dendritic cells and
involving diﬀerent pathways [46, 49, 50]. This is sustained
by the observation that chronic hepatitis B infection is
associated with reduction of dendritic cell functions and
impairment of the innate immune response [51], although
it does not infect immune cells [52]. Toll-like receptor
signalling is downregulated in the liver and blood of HBeAg-
positive individuals [53, 54] which points to potentially
crucial interactions between virions, HBeAg and the innate
immune response. The relative contribution of cytolytic and
non-cytolytic processes in the elimination of HPV cccDNA,
however, is elusive yet.
Taken together, two CARs with speciﬁcity for two
diﬀerent HBV surface proteins are well characterized to date.
Upon retroviral expression, CARs deliver HBV speciﬁcity to
primary human T cells, trigger their activation to secreteHepatitis Research and Treatment 5
proinﬂammatory cytokines, and enable them to eliminate
H B Vi n f e c t e dc e l l sf r o map r i m a r yh u m a nh e p a t o c y t e
culture. Speciﬁc antigen recognition results in proliferative
expansion of redirected T cells which is a key requisite for
eﬀective repopulation after adoptive transfer into patients.
Soluble HB viral particles, however, bind to the CAR-
modiﬁed T cells inducing some activation, at least in vitro,
but do not block redirected T cell activation upon binding to
HBV-infected target cells.
5.CAR-EngineeredTCellsRedirectedAgainst
HIV-1-InfectedCells
Immunotherapy utilizing engineered T cells with speciﬁcity
for virally infected cells has been studied in detail in the
setting of HIV-1 infection. A CAR with a binding domain
derived from a neutralizing anti-gp120 antibody redirects
T cells towards HIV envelope glycoprotein gp120 resulting
in an eﬀector T cell response including cytokine secretion.
Engineered CD8+ T cells induced lysis of HIV-1- infected
CD4+ T cells with high eﬃciencies in vitro [37]. The strategy
was, moreover, adapted to the particular situation of HIV
infection by engineering a CD4-ζ CAR with the extracellular
domain of CD4 which targets HIV env expressed on the
surface of infected cells [54]. The MHC independency
of such interaction allows HIV-speciﬁc targeting of both
CD4+ and CD8+ T cells and may, moreover, circumvent
the ability of HIV to evade T cell recognition through
downregulation of HLA molecules on the surface of infected
cells. CD4-ζ CAR modiﬁed cytotoxic T cells showed antigen-
driven proliferation, cytokine release and cytolytic activity
towards HIV-infected T cells in preclinical studies [55, 56].
Adoptive transfer of ex vivo ampliﬁed, syngeneic, CD4-ζ
CAR modiﬁed CD8+ T cells in HIV-infected twin pairs,
however, revealed a rapid decline in modiﬁed T cells in
the peripheral blood [57]. This may be due to the lack of
CD28 costimulation and the lack of help by CD4+ T cells,
highlighting the need of CD28-ζ CARs and the ex vivo
modiﬁcation of both CD4+ and CD8+ T cell populations.
In a phase II trial coinfusion of autologous CD4-ζ, CAR-
modiﬁed CD4+ and CD8+ T cells with or without IL-2
supplementation in HIV-infected patients with detectable
virus load resulted in persistence of modiﬁed T cells in
long-term [58]. Taken together, CD4-ζ modiﬁed T cell can
inhibit HIV replication, kill HIV-infected cells in vitro,a n d
survive for prolonged periods in vivo. Infusion of CAR
engineered, but not unmodiﬁed, T cells resulted in decrease
inHIVburdeninatleasttwoassaysandatrendtowardfewer
patients with recurrent viremia [59]. Given the rapidity of
the HIV-1 life cycle, timing of cell lysis in the control of
viral replication appears to be crucial since recognition by
anti-gp120 CAR-modiﬁed T cells requires that infected cells
expressassembledviralenvelopeonthesurfaceoftargetcells.
6. Translationto ClinicalUse:
Potency andUnresolvedQuestions
CAR-engineered T cells have been applied in phase-I
clinical trials, mostly in the treatment of malignant diseases,
and several trials are ongoing or in advanced phase of
preparation (for review, see [28] ) .A l lt r i a l sh a v ei nc o m m o n
ex vivo engineering of patient peripheral blood T cells with
the recombinant CAR, extensive ex vivo ampliﬁcation and
reinfusion of those cells, mostly by repetitive applications,
into a patient who is pretreated for lymphoablation to allow
homeostatic expansion of engineered T cells (Figure 1).
Preclinical studies and clinical trials have been designed
based on lessons learned from the preclinical animal
models, for example, the use of a humanized scFv for CAR
binding, inclusion of the CD28 costimulatory domain to
sustain T cell survival, use of γ-retro- or lentiviral vectors
or electroporation for T cell modiﬁcation, inclusion of
homeostatic interleukins to amplify engineered T cells, the
use of both CD4+ and CD8+ T cells or the use of autologous
T cells speciﬁc to viral antigens such as EBV or inﬂuenza
(for review, see [32]). A proof-of-concept clinical trial in
which patients with relapsed or refractory indolent B cell
lymphoma or mantle cell lymphoma were treated with
autologous, anti-CD20 CAR modiﬁed T cells was reported
the Fred Hutchinson Cancer Research Center [26]. Patients
received a total of 20 T cell infusions with minimal toxicities.
Modiﬁed T cells persisted in vivo up to 9 weeks in patients
who additionally received low-dose subcutaneous IL-2
injections. Of the 7 treated patients, 2 maintained a previous
complete response, 1 achieved a partial response, and 4 had
stable disease. Another recent clinical trial by the Brenner
group [60] has shown a correlation between the persistence
of the adoptive transferred T bodies and the clinical
outcome. While a number of trials in cancer treatment have
recently been reported, adoptive T cell therapy aiming to
eliminate HBV infected cells has not been performed so far.
The two obvious advantages of the CAR strategy to
eliminate HBV-infected cells by adoptive T cell therapy are
the production of nearly unlimited numbers of immune cells
with deﬁned speciﬁcity and the MHC-independent targeting
of virally encoded cell surface proteins (Table 1). Virus
infected cells frequently downregulate proteins associated
with antigen processing and presentation including MHC,
which renders the infected cell invisible to T cells. A MHC-
independent T cell attack redirected by an antibody derived
CAR may be of signiﬁcant advantage in this situation.
While the CAR structure plays key roles in optimizing the
function of engineered T cells, critical to the success of
therapy will be the choice of targeted antigen. By using
antibodies for binding, a variety of viral antigen epitopes
can potentially be targeted, each of which needs to be
considered with respect to several parameters including the
accessibility for the antibody and the capacity to cluster the
CAR on the T cell surface. The spatial relationship of the
targeted epitope with respect to the membrane topology of
the target cell has to be taken into account since an optimal
T cell-to-target cell spacing distance seems to be required
for the most eﬀective T cell response. Phage display and
other powerful selection systems are assumed to provide a
plethora of binding domains to target various epitopes of
HBV encoded surface proteins. The aﬃnity of a given scFv
can moreover be increased or reduced [61, 62]i no r d e rt o
improve speciﬁcity and optimize T cell activation. Increase6 Hepatitis Research and Treatment
Conditioning
chemotherapy
Transfer
CAR engineered
Tc e l l s
Analyse safety ex vivo
IL-2 T cell
“support”
therapy
Test for virus
clearance
Expand CAR
engineered T cells
ex vivo
Collect T cells
from patient
retro-/ lenti-viral
gene transfer
Engineer
anti-HBV CAR
retro-/ lenti-viral
packaging
CD3ζ
scFv
CD3ζ
scFv
CD28
Patient with chronic
hepatitis B
Figure 1:AdoptivecelltherapyusingCARengineeredTcells.TcellsfromtheperipheralbloodofapatientwithchronichepatitisBisobtained,
ex vivo stimulated to proliferate, engineered with HBV speciﬁc CAR by retro- or lentiviral gene transfer, ampliﬁed to therapeutic numbers
and readministered by i.v. infusion to the patient along with low dose IL-2. To allow homeostatic expansion of adoptively transferred T
cells, patient may be pretreated by nonmyeloablative lymphodepletion with cyclophosphamide and ﬂudarabine. T cell application may be
performed repetitively using the same batch of ex vivo CAR engineered T cells.
in aﬃnity, however, does not necessarily result in increased
activation of redirected T cells [61].
The aﬃnity dependent cross-reactivity to homologous
antigens physiologically expressed on healthy tissues as well
as potential inactivation of CARs by soluble antigens have to
be taken into account. This may counterbalance advantages
of increasing aﬃnity and needs careful consideration and as
such, empirical testing of the respective CARs.
Understanding of the mechanisms of CAR mediated
killing of target cells is still at an early stage. In vitro analyses
indicate that CAR redirected killing occurs predominantly
via perforin/granzyme and less via Fas/FasL [63]. It is most
likely that CAR-engineered T cells can proliferate and kill
multiple targets, thereby amplifying the anti-viral response.
TraﬃckingofTcellstothesiteofinfectionwilldetermine
the clinical success of adoptive T cell therapy. Engineered T
cells are likely to pass the liver during ﬁrst round of circula-
tion. Whether they will inﬁltrate the tissue and kill infected
hepatocytesneedstobeproveninanimalstudies.Intargeting
HBV-infected hepatocytes, however, a number of questions
s t i l lr e m a i nt ob es o l v e d( Table 2). Does strong binding to
individualHBV-infectedcellstraptheTcellslocally?Willthe
immune suppressive microenvironment of the liver silence
transferred T cells? What eﬀect would circulating HBsAg or
subviral HBV particles have on traﬃcking and activation of
engineered T cells taking into account that the surface of
HBV particles seems suﬃcient to induce CAR-mediated T
cell activation?
Ab e n e ﬁ c i a le ﬀector cell-to-target cell ratio at the site of
HBV infected liver cells is likely to be required for eﬃcient
target cell elimination. An estimation based on clinical
data, however, is not yet available from trials performed
in tumor patients; however, higher numbers of engineered
T cells, that is, 109−1010 c e l l s ,p e rd o s ea sw e l la sm u l t i p l e
applications are likely to increase eﬃcacy. Antigen-driven
ampliﬁcation of engineered T cells, on the other hand, may
help to achieve a suﬃcient T cell response but may also be
accompaniedbyaﬂareofhepatitis.Moreover,autoimmunity
may potentially result from “oﬀ-target” T cell activation
and may lead to targeting of healthy tissues. In case ofHepatitis Research and Treatment 7
Table 2: Open questions concerning the clinical use of CAR-engineered T cells in the treatment of chronic hepatitis B.
(i) Does binding to individual HBV infected cells trap the anti-HBV CAR T cells locally in the liver?
(ii) To which extend are HBV-infected hepatocytes eliminated by engineered T cells?
(iii) Will the immune suppressive microenvironment silence transferred T cells?
(iv) What eﬀect would circulating HBsAg or subviral HBV particles have on the activation of engineered T cells? Do soluble HBV particles
induce CAR mediated “on-target oﬀ-organ” T cell activation?
(v) Is HBV-speciﬁc T cell memory induced?
(vi) How can induction of anergy of engineered T cells be prevented?
(vii) Do inﬂammatory cytokines secreted by activated T cells attract a second wave of nonspeciﬁc inﬂammatory cells, and how do these
cells comodulate the anti-HBV T cell response?
virally encoded antigens, cross-reactivity with physiologi-
cally expressed human antigens is unlikely as long as scFv
mediated CAR activation is speciﬁc. Autoimmunity has been
a major problem in CAR targeting of carboanhydrase IX
(G250), a renal cell carcinoma antigen also expressed at
low levels on bile duct epithelia [24] and in a recent trial
targeting Her2/neu (ErbB2) with fatal outcome [63]. In
the renal cell carcinoma trial, toxicity was controlled using
steroids to deplete modiﬁed T cells. Since virally encoded
proteins are mostly genuine, the choice of targeted antigen
is less critical than targeting tumor associated antigens which
most frequently are physiologically expressed at lower levels
in healthy tissues. Control procedures to ensure that oﬀ-
target toxicities are kept to a minimum, however, need
careful evaluation. Despite thoroughly pre-clinical safety
testing, controlling the engineered T cell in vivo performance
represents a mandatory option. Novel gene suicide systems
using tagged CAR molecules which can be targeted by T
cell depleting antibodies in vivo [64] and the induction
of endogenous apoptosis pathways [65] have recently been
developed to permit speciﬁc depletion of the engineered T
cells rather than the need for total T cell depletion strategies.
Taken together, strong arguments support the develop-
mentofthisformofadoptivecelltherapyforthetreatmentof
persistentviralinfections. Since theinitial descriptions ofthe
approach nearly 20 years ago, most of the early technological
hurdles concerning the generation of antigen-speciﬁc T cells
have been overcome. Insight is rising how eﬀective CAR
redirected T cells are when compared to “natural T cells”
upon adoptive transfer in vivo. While ﬁrst clinical trials
show the safety, feasibility, and potential therapeutic activity
of adoptive T-cell therapies using this approach, concerns
raisedthatautoimmunityduetocross-reactivitywithhealthy
tissues is a major safety issue. Introduction of genes into
T cells using retroviral vectors has been proved safe. It
is clear today that the risk of leukaemia that occurred in
patients receiving retroviral vector-mediated gene transfer
into hematopoietic stem cells does not exist for mature T
cells [66]. The antibody whose scFv will serve to redirect
the engineered T cells has to be carefully tested both in
terms of speciﬁcity and aﬃnity to diminish the risk of
damaging essential healthy tissues. Despite a number of
unresolved questions, engineered T cells redirected by a
HBV S or L antigen speciﬁc CAR, potentially combined
with ablation of suppressor cells, may provide an attractive
strategy to eliminate HBV-infected cells by implementation
of an eﬀective virus antigen-speciﬁc CTL response. Animal
experiments and subsequent clinical trials need to determine
whether CAR redirected T cell activation can establish full
immunological control of HBV infection.
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